General MedicationsSUBCUTANEOUSGeneric
TEGSEDI
INOTERSEN SODIUM
Standard Dose
EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Discontinued
Summary
Approval overview TEGSEDI is listed in Drugs@FDA under application 211172 (NDA).
Review priority: N/A Marketing status: Discontinued Active ingredient INOTERSEN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML) Sponsor AKCEA THERAPS Submission history Latest submission status date: 2024-11-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview TEGSEDI is listed in Drugs@FDA under application 211172 (NDA). Review priority: N/A Marketing status: Discontinued Active ingredient INOTERSEN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML) Sponsor AKCEA THERAPS Submission history Latest submission status date: 2024-11-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.